Elutia (ELUT) Cantor Global Healthcare Conference 2025 summary

Company overview and product innovation

• Focuses on drug-eluting biologics, combining biological matrices with active pharmaceuticals to improve patient outcomes in implantable devices.

• EluPro, their lead product, is a biologic envelope for pacemakers and defibrillators, offering antibiotic protection and tissue integration.

• EluPro has FDA approval and commercial launch, with strong early adoption and a partnership with Boston Scientific to accelerate growth.

• Expansion into breast reconstruction with NXT-41X, a drug-eluting biologic targeting a large unmet need and market opportunity.

Market dynamics and commercialization strategy

• The U.S. pacemaker protection market is valued at $600 million, previously dominated by a plastic-based competitor.

• EluPro differentiates with a biological matrix, appealing to device makers outside Medtronic and capturing a significant market share.

• Currently in 161 active accounts, adding 12–15 new VAC approvals monthly, aiming to scale to 1,600 centers with GPO and Boston Scientific support.

• Boston Scientific drives about 30% of sales, with their reps boosting overall product adoption across device brands.

Financial performance and operational leverage

• Gross margin improved from mid-50s% to low 60s% due to scaling and operational efficiencies.

• EluPro expected to reach 70%+ gross margin as lot sizes increase and more testing is brought in-house.

• Other business lines, such as SimpliDerm and cardiovascular products, contribute to margins, with cardiovascular products exceeding 80%.